공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

암면역 진단 시장 : COVID-19의 영향과 갱신에 기반한 암면역 진단 시장 예측과 분석(2021-2025년)

Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2021 to 2025

리서치사 Howe Sound Research
발행일 2021년 02월 상품 코드 987593
페이지 정보 영문 263 Pages
가격
US $ 6,995 ₩ 7,906,000 PDF (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 11,862,000 PDF (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 15,818,000 PDF (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



암면역 진단 시장 : COVID-19의 영향과 갱신에 기반한 암면역 진단 시장 예측과 분석(2021-2025년) Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2021 to 2025
발행일 : 2021년 02월 페이지 정보 : 영문 263 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

현재 암치료 혁명이 진행되고 있습니다. 신체의 자연스러운 면역 방어 이용에 기반한 새로운 치료법은 전례 없는 성공을 거두고 있습니다. 그러나 적절한 치료법을 선택하기 위해서는 진단, 특히 바이오마커가 절실하게 필요할 것으로 생각됩니다.

세계의 암면역 진단(Immuno-Oncology Diagnostics) 시장에 대해 조사했으며, 시장 정의, 기술 가이드, 시장 동향, 성장 촉진요인 및 억제요인, 최근의 개발, 어세이 종류·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

  • 마켓 가이드
  • COVID-19 팬데믹 상황 분석과 영향
  • 경영진 및 마케팅 스탭을 위한 가이드
  • 투자 애널리스트 및 경영 컨설턴트를 위한 가이드

제1장 서론과 시장 정의

  • 암면역 진단이란 무엇인가?
  • 암면역 : 다가오는 치료법
    • 주도적인 역할을 완수하는 암면역 진단
  • 시장 정의
  • 조사 방법
  • 미국의 의료 시장과 임상 검사 : 전망
    • 임상 검사를 위한 미국의 메디케어 지출

제2장 면역요법 : 면역 기술 가이드

  • 면역 시스템
    • 자연 면역 시스템
    • 적응 면역 시스템
    • 면역 감시 시스템
  • 암면역 진단
    • 체크포인트 어세이
    • 사이토카인 어세이
    • 게놈 생식세포계열
    • 게놈 종양
    • 종양 미세환경
    • 기타

제3장 업계의 개요

  • 시장 기업 동향
    • 학술 조사실
    • 진단 테스트 개발자
    • 게놈 계측 공급업체
    • 의약품/시약 공급업체
    • 독립 테스트 실험실
    • 공립 국립/지역 연구소
    • 병원 실험실
    • 의사 실험실
    • 감사 기관
    • 인증 기관

제4장 시장 동향

  • 성장 촉진요인
    • 결과 가능성
    • 동반진단
    • 자금 조달
    • 테크놀러지 환경
    • 타겟 솔루션
  • 성장 억제요인
    • 진단의 복잡한 역할
    • 임상시험의 역할
    • 프로토콜
  • 진단 기술 개발
    • 조합 : 문제와 복잡성
    • 진단의 역할 변화
    • 다중화와 Foundation One
    • 디스럽션 다이나믹
    • 바이오마커의 경쟁
    • 향후 5년간 전망

제5장 암면역 진단 : 최근의 진전

  • 최근의 개발
    • OncoDNA : HalioDx 사용에 의한 북미로의 확대
    • Adaptive Biotechnologies : 2분기, 솔루션의 ImmunoSeq 계약에 서명
    • Qiagen : 암면역 포트폴리오 확대
    • COVID-19와 싸우기 위해서 리디렉트된 면역 프로파일링 시스템
    • IncellDx : PD-L1 검출 특허를 취득
    • FDA : Trastuzumab의 CDx를 승인
    • ArcherDx : 암면역을 위한 AstraZeneca와의 제휴
    • Agilent PD-L1 어세이 : FDA 승인을 취득
    • Biocare Medical : 7개 새로운 IVD 항체를 발표 등

제6장 주요 면역요법 기업 개요

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMírieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako(Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

제7장 세계의 암면역 진단 시장

  • 국가별 세계 시장 개요
    • 차트
  • 어세이 종류별 세계 시장 : 개요

제8장 세계 시장 : 어세이 종류별

  • 체크포인트
  • 사이토카인
  • 생식세포계 유전학
  • 유전적 종양
  • 종양 미세환경
  • 기타

제9장 부록

  • 연도별 : FDA 암 치료제 승인
  • 2010년부터 2016년에 개시된 임상시험
  • 암치료 유병률
KSM 21.02.18

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Overview of Innate and Adaptive Immunity
  • Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 5 FDA Approved Companion diagnostics in Cancer treatment
  • Table 6 Market Players by Type
  • Table 7 Five Factors Driving Growth
  • Table 8 Three Factors Limiting Growth
  • Table 9 - Global Market by Region
  • Table 10 Global Market by Assay Type
  • Table 11 Checkpoint by Country
  • Table 12 Cytokine by Country
  • Table 13 Germline Genetic by Country
  • Table 14 Genetic Tumor by Country
  • Table 15 Tumor Microenvironment by Country
  • Table 16 Other by Country

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Helper T Cell Roles
  • Figure 4 Antibody Diagram
  • Figure 5 Macrophages attack a Cancer Cell
  • Figure 6 The Tumour Micro Environment
  • Figure 7 Comparing IO Diagnostic and Traditional Testing
  • Figure 8 Growth rates of IO DiagnosticTechnologies
  • Figure 9 Global Market Density Chart
  • Figure 10 Global Market by Assay Type - Base vs. Final
  • Figure 11 Global Market by Assay Type Base Year
  • Figure 12 Global Market by Assay Type End Year
  • Figure 13 Assay Type Share by Year
  • Figure 14 Assay Type Segments Growth
  • Figure 15 Checkpoint Growth
  • Figure 16 Cytokine Growth
  • Figure 17 Germline Genetic Growth
  • Figure 18 Genetic Tumor Growth
  • Figure 19 Tumor Microenvironment Growth
  • Figure 20 Other Growth
  • Figure 21 FDA Cancer Drug Approvals by Year
  • Figure 22 Clinical Trials for Immunotherapy by Year
  • Figure 23 Pie Chart of Prevalence of Cancer Treatments

OVERVIEW:

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes the focus of research.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity and the surprising impact of COVID-19 on what might seem to be an unrelated area.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Market Guides
  • i. Situation Analysis & Impact of COVID-19 Pandemic
  • ii. Guide for Executives and Marketing Staff
  • iii. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1 What are Immuno-Oncology Diagnostics?
  • 1.2 Immuno-oncology - the looming cure
    • 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 1.3 Market Definition
    • 1.3.1 Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies

  • 2.0 The Immune System
    • 2.0.1 Innate immune system
      • 2.0.1.1 Surface barriers
      • 2.0.1.2 Inflammation
      • 2.0.1.3 Complement system
      • 2.0.1.4 Cellular barriers
      • 2.0.1.5 Natural killer cells
    • 2.0.2 Adaptive immune system
      • 2.0.2.1 Lymphocytes
      • 2.0.2.2 Killer T cells
      • 2.0.2.3 Helper T cells
      • 2.0.2.4 Gamma delta T cells
      • 2.0.2.5 B lymphocytes and antibodies
    • 2.0.3 Tumor immunology - the immune surveillance system
  • 2.1 Immuno Oncology Diagnostics
    • 2.1.1 Checkpoint Assays
      • 2.1.1.1 Outlook for Checkpoint Assays
    • 2.1.2 Cytokine Assays
      • 2.1.2.1 Outlook for Cytokine Assays
    • 2.1.3 Genomic Germline
      • 2.1.3.1 Outlook for Genomic Germline
    • 2.1.4 Genomic Tumour
      • 2.1.4.1 Outlook for Genomic Tumour
    • 2.1.5 Tumor Microenviroment
      • 2.1.5.1 Outlook for Tumor Micro Environment
    • 2.1.6 Others
      • 2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Genomic Instrumentation Supplier
      • 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4 Pharmaceutical/Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Outcome potential
    • 4.1.2 Companion Diagnostics
    • 4.1.3 Funding
    • 4.1.4 Technology Environment
    • 4.1.5 Target Solutions
  • 4.2 Factors Limiting Growth
    • 4.2.1 Complex Role of Diagnostics
    • 4.2.2 Clinical Trials Role
    • 4.2.3 Protocols
  • 4.3 Diagnostic Technology Development
    • 4.3.1 Combinations - Issues and Complexity
    • 4.3.2 Shifting Role of Diagnostics
    • 4.3.3 Multiplexing and Foundation One
    • 4.3.4 The Disruption Dynamic
    • 4.3.5 The Race for Biomarkers
    • 4.3.6 The Next Five Years

5. Cancer Immuno-Oncology Diagnostics Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
      • OncoDNA use HalioDx to Expand into North America
      • Adaptive Biotechnologies, Q2 Solutions Sign Agreement for ImmunoSeq
      • Qiagen Expands Immuno-Oncology Portfolio
      • Immune Profiling System Redirected to Fight COVID-19
      • IncellDx Awarded PD-L1 Detection Patent
      • FDA Approves CDx for Trastuzumab
      • Promega Nabs CE Mark for Microsatellite Instability IVD
      • ArcherDx partners with AstraZeneca for Immuno-Oncology
      • Germline Results Guides Precision Therapy
      • Agilent PD-L1 Assay Gets FDA Approval
      • Bayer, OrigiMed Form Companion Diagnostic Development Alliance
      • Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
      • SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
      • Signatures
      • Biocare Medical Launches 7 Novel IVD Antibodies
      • Oncocyte to Acquire Insight Genetics for $12M
      • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
      • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
      • Generex to Merge with NuGenerex Immuno-Oncology
      • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
      • Companion Diagnostics for Cancer Therapies
      • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
      • Breast Cancer
      • Icon Acquires MolecularMD
      • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
      • Tumor Mutational Burden as Predictor of Immunotherapy Success

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMírieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. The Global Market for Immuno-Oncology Diagnostics

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Assay Type - Overview
    • 7.2.1 Table - Global Market by Assay Type
    • 7.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Assay Type - Base Year
    • 7.2.4 Chart - Global Market by Assay Type - End Year
    • 7.2.5 Chart - Global Market by Assay Type - Share by Year
    • 7.2.6 Chart - Global Market by Assay Type - Segments Growth

8. Global Immuno-Oncology Diagnostic Markets - By Assay Type

  • 8.1 Checkpoint
    • 8.1.1 Table Checkpoint - by Country
    • 8.1.2 Chart - Checkpoint Growth
  • 8.2 Cytokine
    • 8.2.1 Table Cytokine - by Country
    • 8.2.2 Chart - Cytokine Growth
  • 8.3 Germline Genetic
    • 8.3.1 Table Germline Genetic - by Country
    • 8.3.2 Chart - Germline Genetic Growth
  • 8.4 Genetic Tumor
    • 8.4.1 Table Genetic Tumor - by Country
    • 8.4.2 Chart - Genetic Tumor Growth
  • 8.5 Tumor Microenvironment
    • 8.5.1 Table Tumor Microenvironment - by Country
    • 8.5.2 Chart - Tumor Microenvironment Growth
  • 8.6 Other
    • 8.6.1 Table Other - by Country
    • 8.6.2 Chart - Other Growth

9. Appendices

  • 9.1 FDA Cancer Drug Approvals by Year
  • 9.2 Clinical Trials Started 2010 to 2016
  • 9.3 Prevalence of Cancer Treatments
Back to Top
전화 문의
F A Q